Navigation Links
Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
Date:12/8/2009

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, announced today that it will be presenting six studies focusing on MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium (SABCS), one of the premiere conferences in breast cancer research worldwide. The SABCS will take place December 9-13, at the Henry B. Gonzalez Convention Center in San Antonio, Texas, USA.

Agendia's studies to be presented at the SABCS further establish the broad predictive and prognostic power of MammaPrint, the only FDA-cleared breast cancer recurrence test available to patients and physicians. Conference attendees can meet the Agendia team at booth #556.

    Study results will be discussed at the following sessions:
    Date: Thursday, December 10, 2009
    Time: 5:30 pm - 7:30 pm
    Poster presentation (102)

Combining Genomic Profiling (70 Gene-MammaPrint) with Nodal Status Allows to Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies

Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I, Delaloge S, van 't Veer L. Institut Gustave Roussy, Villejuif, France; Netherlands Cancer Institute, Amsterdam, The Netherlands; European Institute of Oncology, Milan, Italy; Agendia BV, Amsterdam, The Netherlands.

Date: Friday, December 11, 2009

Time: 7 am - 9 am

Poster presentation (2026)

Basal-, Luminal-, and HER2- Molecular Subtype, and the MammaPrint 70-Gene Signature as Predictors of Response to Neoadjuvant Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide (TAC), or AC and Nab-Paclitaxel and Carboplatin +/- Trastuzumab in Patients (pts) with Stage II-III and Inflammatory Breast Cancer (BC)

Somlo G, Lau S, Frankel P, Garberoglio C, Kruper L, Yen Y, Luu T, Hurria A, Chung CT, Mortimer J, Yim J, Paz IBe, Krijgsman O, Delahaye L, Stork-Sloots L, Bender R. City of Hope Comprehensive Cancer Center, Duarte, CA; Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA.

Date: Saturday, December 12, 2009

Time: 7 am - 9 am

Poster presentation (4049)

The 70-Gene Profile (MammaPrint) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older

Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas AM, Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands

    Date: Sunday, December 13, 2009
    Time: 7 am - 8:30am
    Poster presentation (6131)
    Molecular Subtype Profile Reveals Therapy Predictive Power

de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM. Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..

Date: Sunday, December 13, 2009

Time: 7 am - 8:30am

Poster presentation (6146)

Biological Functions of Genes in the 70-Gene MammaPrint Tumor Expression Profile Reflect Molecular Mechanism of Tumor Metastasis

Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de Snoo F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.

About MammaPrint(R)

MammaPrint is the first and only breast cancer recurrence test cleared by the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets three products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
2. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
3. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
4. Time Magazine Names Agendia Test a Best Invention of 2007
5. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans
8. Hospice Foundation of America Presents Webinar on Bereavement Camps for Kids: Benefits and Challenges
9. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
10. Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference
11. Makers of Powerful Painkillers Present Safety Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Brooklyn, NY (PRWEB) , ... June 27, 2016 ... ... is using cutting edge technology to revolutionize the emergency ambulance transport experience for ... Many are aware of how Uber has disrupted the taxi industry through the ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: